Difference between revisions of "Fosaprepitant (Emend for Injection)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. Fosaprepitant is a prodrug of Aprepitant (Emend). Aprepitant is able to cros...") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (13 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. | + | Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. Fosaprepitant is a prodrug of [[Aprepitant (Emend)]]. Aprepitant is able to cross the blood-brain barrier and blocks substance P activation of tachykinin family neurokinin 1 (NK1) receptors, which reduces the incidence of acute and delayed emesis.<ref name=insert>[http://www.merck.com/product/usa/pi_circulars/e/emend_iv/emend_iv_pi.pdf Fosaprepitant (Emend) package insert]</ref><ref>[[:File:Fosaprepitant.pdf | Fosaprepitant (Emend) package insert (locally hosted backup)]]</ref><ref>[http://www.emend.com/ Emend manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information available | <br>Extravasation: no information available | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 12: | Line 12: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2008-01-25: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022023lbl.pdf Approved] for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose [[cisplatin]] and prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. |
| − | + | ==History of changes in EMA indication== | |
| + | *2008-01-11: Initial authorization as Ivemend | ||
==Also known as== | ==Also known as== | ||
| − | Emend for Injection, | + | *'''Generic name:''' fosaprepitant dimeglumine |
| + | *'''Brand name:''' Emend for Injection, Ivemend, Proemend | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| + | [[Category:Intravenous medications]] | ||
[[Category:Emesis prevention]] | [[Category:Emesis prevention]] | ||
[[Category:Neurokinin 1 (NK1) antagonists]] | [[Category:Neurokinin 1 (NK1) antagonists]] | ||
| + | [[Category:EMA approved in 2008]] | ||
| + | [[Category:FDA approved in 2008]] | ||
Latest revision as of 01:01, 29 June 2024
General information
Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. Fosaprepitant is a prodrug of Aprepitant (Emend). Aprepitant is able to cross the blood-brain barrier and blocks substance P activation of tachykinin family neurokinin 1 (NK1) receptors, which reduces the incidence of acute and delayed emesis.[1][2][3]
Route: IV
Extravasation: no information available
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the Fosaprepitant (Emend) package insert[1]
- Fosaprepitant (Emend) package insert (1/25/2008 version), has more extensive patient information.
- Fosaprepitant (Emend) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2008-01-25: Approved for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin and prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
History of changes in EMA indication
- 2008-01-11: Initial authorization as Ivemend
Also known as
- Generic name: fosaprepitant dimeglumine
- Brand name: Emend for Injection, Ivemend, Proemend